|
GARDASIL FACTS |
Gardasil Fact Sheet
 First
and only vaccine to prevent:
- Cervical cancer
- Cervical, Vulvar and vaginal pre-cancer caused by HPV types 16 and 18.
- Low-grade and precancerous lesions
- Genital warts caused by HPV types 6 and 11.
Gardasil
was approved on June 8 by the Food and Drug Administration (FDA) for the
use in girls and women aged 9-26 years.
In clinical studies:
Gardasil
prevented 100 percent of HPV 16 and 18 related cervical cancers in
women.
Gardasil
prevented 95 percent of low -grade cervical lesions and pre-cancers
cause by HPV 6, 11, 16 and 18.
Gardasil
prevented 99 percent of cases of genital warts cause by HPV 6 or 11.
If a
woman is infected with one of the 6, 11, 16 and 18 HPV types, Gardasil
will protect against clinical diseases caused by the remaining HPV
types, but it will not alter the already existing infection.
Administration:
Gardasil
is a ready-to-use, three dose, intramuscular vaccine.
Gardasil
should be administered in three injections in 3 different intramuscular
injections (the upper arm or upper thigh) over a six-month period.
First
dose administered on elected date, second dose two months after the
first dose, and the third dose six months after the first dose.
Gardasil
does not substitute routine cervical cancer screening.
Women who
receive Gardasil should continue to undergo cervical cancer screening
per standard of care.
Source: Courtesy of Gardasil
Note: The above
information is intended to supplement, not substitute for, the expertise
and judgment of your physician, pharmacist, or other healthcare
professional. It is not intended to diagnose a health condition, but it
can be used as a guide to help you decide if you should seek
professional treatment or to help you learn more about your condition
once it has been diagnosed.
Posted 20/JAN/07
|
|
